Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Y-Prime is a company specializing in eClinical solutions, including Interactive Response Technology (IRT), electronic Clinical Outcome Assessments (eCOA), and clinical trial supplies management. Founded in 2006, Y-Prime focused on delivering innovative software and services to streamline clinical trials for pharmaceutical companies, biotechs, and contract research organizations (CROs). In September 2021, Y-Prime was acquired by ICON plc, a global provider of drug and device development and commercialization services. Y-Prime now operates as part of ICON, contributing its expertise and technology to ICON's broader suite of clinical research solutions.
Served as the global headquarters, housing executive leadership, R&D, product development, and core operational teams for its eClinical solutions prior to its acquisition by ICON.
Modern office space designed to foster collaboration and innovation in clinical trial technology. Specific architectural details are not widely publicized but facilities were aligned with a technology-focused company.
Prior to acquisition, Y-Prime was known for a culture focused on innovation, customer success, and a collaborative environment aimed at improving clinical trials. It fostered a fast-paced, technology-driven atmosphere.
The Malvern headquarters was the central hub for Y-Prime's strategic decisions, technological advancements, and global operations in the eClinical market before its integration into ICON.
Prior to its acquisition by ICON, Y-Prime supported global clinical trials through its strategically located offices in North America and Europe, complemented by remote teams. Its eCOA, IRT, and clinical trial supply management solutions were designed for worldwide deployment, supporting clients in the pharmaceutical, biotech, and CRO industries across numerous countries and languages.
230 Sugartown Rd, Suite 100
Malvern
Pennsylvania
USA
Address: Information on specific street address not readily available post-acquisition.
Supported East Coast clients, project management, and contributed to Y-Prime's expanding presence and service delivery in North America.
Address: Information on specific street address not readily available post-acquisition.
Facilitated service delivery to European and UK pharmaceutical and biotech clients, ensuring compliance with regional regulations and supporting clinical trials in the EMEA region.
Address: Information on specific street address not readily available post-acquisition.
Contributed to the development and maintenance of Y-Prime's eClinical platform, providing technical expertise and support for global operations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, YPrime' leadership includes:
YPrime has been backed by several prominent investors over the years, including:
Following its acquisition by ICON plc in September 2021, Y-Prime's executive leadership was integrated into ICON's structure, or individuals transitioned to other roles or departed. As such, distinct 'Y-Prime' branded executive hires or exits in the last 12 months are not applicable, as leadership functions now operate under ICON. Major leadership changes occurred around the 2021 acquisition period.
Discover the tools YPrime uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its full integration with ICON, Y-Prime commonly used specific email patterns for its corporate communications. The most prevalent format was [first_initial][last]@[companydomain].com.
flast@y-prime.com (e.g., jdoe@y-prime.com)
Format
sblackburn@y-prime.com
Example
90%
Success rate
Fierce Biotech • September 2, 2021
ICON plc acquired Y-Prime, an eClinical solutions provider, to enhance its capabilities in digital health, patient communication, and data collection for clinical trials. This strategic move aimed to integrate Y-Prime's IRT and eCOA technologies into ICON's offerings....more
PR Newswire • May 22, 2019
Y-Prime secured a strategic growth investment from Flexpoint Ford, a private equity firm. This investment was intended to accelerate Y-Prime's expansion, enhance its product development pipeline, and support its continued growth in the eClinical solutions market globally....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including YPrime, are just a search away.